188 East Blaine Street
Suite 200
Seattle, WA 98102
United States
206 788 4545
https://www.alpineimmunesciences.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 142
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Mitchell H. Gold M.D. | Executive Chairman & CEO | 1,02M | S.O. | 1968 |
Dr. Stanford Peng M.D., Ph.D. | President and Head of Research & Development | 940,1k | S.O. | 1971 |
Mr. Paul Rickey | Senior VP, CFO, Treasurer & Secretary | 691,1k | S.O. | 1979 |
Mr. Ulrich Martin Fuhs | VP of Finance & Chief Accounting Officer | S.O. | S.O. | 1968 |
Ms. M. Christina Yi | Chief Technology Officer | S.O. | S.O. | 1976 |
Ms. Michelle Greenblatt | Director of Investor Relations & Corporate Communications | S.O. | S.O. | S.O. |
Dr. Remy Durand Ph.D. | Chief Business Officer | S.O. | S.O. | 1986 |
Dr. Andrew Seth Sandler M.D. | Chief Medical Officer | S.O. | S.O. | 1965 |
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
L’ISS Governance QualityScore de Alpine Immune Sciences, Inc. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 8; Société : 8; Droits des actionnaires : 8; Compensation : 9.